aextracker schreef op 26 januari 2021 21:05:
www.pharming.com/sites/default/files/...Afgelopen week events in USA , waar CEO SdV presenteerde;
For the remainder of 2020 and into 2021, the Company expects:
- Subject to progression of the COVID-19 pandemic in the US; continued growth in revenues from sales of RUCONEST®, mainly driven by the US and expanded EU operations
- Maintenance of positive net earnings during the year
- Continued investment in the expansion of production of RUCONEST® in order to ensure continuity of supply to the growing markets in the US, Europe, China and the RoW
- Investment in the ongoing clinical trials for pre-eclampsia and acute kidney injury, severe pneumonia as a result of COVID-19 infection and support investigators wishing to explore additional indications for rh C1INH
- Investment in the continuing registration-enabling study for leniolisib for APDS, leading to headline data in mid 2021 and launch in H2 2022
- Investment in upscaling and IND enabling studies for a-glucosidase in Pompe disease
- Investment in acquisitions and in-licensing of other new development opportunities and assets as these occur
- Increasing marketing activity where this can be profit-enhancing for Pharming
Medio 2021 aldus een eerstvolgende update i.r.t. pipleine versterker leniolisib.
Meer van dergelijke "in liicensing deals""te verwachten komende 1-3 jaar. wsl. vnl. gezocht in bijzondere ziektes die in de behandelingsmethodiek en commercialisatie aansluiten bij Ruconest.
RvC & Advosiry Board is er alvast op ingeregeld, net als de kennis en expertise van de CFO. Komen derhalve 2-3 bewogen en dynamische jaren aan bij Pharming.